Has Julie Talavera, MD received payments from drug or device companies?

Yes. Drug and device makers reported $49,366 in general payments to Julie Talavera, MD across 1,194 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Julie Talavera, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Julie Talavera, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Julie Talavera, MD

Endocrinology, Diabetes & Metabolism · Metairie, LANPI 1124268008

Payments from drug & device makers

$49,366in general payments, 2019–2025

Across 1,194 payments — averaging $41.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$27K
Abbott$6K
Lilly USA, LLC$2K
Amgen$2K
AstraZeneca$2K
Dexcom, Inc.$1K
plus $10K from 51 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	176	$26,944
Abbott	122	$5,731
Lilly USA, LLC	107	$1,707
Amgen(2 entities)	72	$1,630
AstraZeneca(2 entities)	67	$1,525
Dexcom, Inc.	63	$1,396
Xeris Pharmaceuticals, Inc.	68	$1,024
Corcept Therapeutics	46	$971
Sanofi-aventis U.S. LLC	54	$794
Boehringer Ingelheim	41	$639
IBSA Pharma Inc.	29	$558
AbbVie	34	$517
Bayer	32	$511
Medtronic(2 entities)	32	$497
Radius Health, Inc.	25	$495
BETA Bionics, Inc.	12	$481
Lifescan, Inc.	24	$416
Amneal Pharmaceuticals LLC	28	$414
BD	20	$363
Mannkind Corporation	18	$359
Merck	18	$270
Insulet Corporation	6	$254
Johnson & Johnson	14	$203
Zealand Pharma US, Inc.	11	$180
Antares Pharma, Inc.	8	$158
Amarin Pharma, Inc.	5	$99
Ultragenyx Pharmaceutical Inc.	5	$97
Novartis	5	$88
Clarus Therapeutics Inc.	5	$86
Tandem Diabetes Care, Inc.	3	$82
Recordati_rare_diseases_inc.	3	$63
Ascensia Diabetes Care US Inc.	3	$63
Sequel Med Tech, LLC	3	$63
Shire North American Group Inc	4	$59
Rhythm Pharmaceuticals, Inc.	2	$50
Intra-sana Laboratories	2	$47
Madrigal Pharmaceuticals	2	$46
Almatica Pharma LLC	2	$44
Rochester Medical Corporation	1	$43
Ascendis Pharma Endocrinology Inc	2	$40
Nevro Corp.	2	$34
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$34
Acella Pharmaceuticals, LLC	2	$32
Averitas Pharma Inc.	1	$28
Embecta Corp.	1	$23
GRT US Holding, Inc.	1	$22
Neurocrine Biosciences, Inc.	1	$21
Kyowa Kirin, Inc.	1	$21
Cequr Corporation	1	$20
Astellas Pharma US Inc	1	$18
Pfizer	1	$17
Arbor Pharmaceuticals, Inc.	1	$17
Avion Pharmaceuticals	1	$16
Halozyme Inc	1	$15
Ferring Pharmaceuticals Inc.	1	$15
Currax Pharmaceuticals LLC	1	$14
Acerus Pharmaceuticals Corporation	1	$12

How this compares

$49,366 in reported general payments places this provider in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana →

Medicare billing

Part B allowed, 2024

$109,349

Medicare patients

400

Services billed

1,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Metairie

Tuan Huy TranMetairie$2M
Jonathan WiseMetairie$463K
Joseph MurrayMetairie$7K
Miguel RiveraMetairie$7K
Harold MillerHammond$1.1M
Timothy GilbertBaton Rouge$985K
Justin FontenotLafayette$905K
Vivian FonsecaNew Orleans$700K
Frank GreenwayBaton Rouge$669K
Abdul KhanHammond$587K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →